Meyers & Flowers warns MS Patients about the Zinbryta’s Removal from the Global Market
Meyers & Flowers is warning multiple sclerosis patients who have taken or are taking Zinbryta about reports of serious, and at times fatal, issues of encephalitis and meningoencephalitis brain inflammation cases due to the drug.
Just two years after receiving U.S. Food and Drug Administration (FDA) approval, Biogen and AbbVie’s multiple sclerosis-drug Zinbryta (daclizumab) is being removed from the global market after the European Medicines Agency (EMA) recommended its immediate suspension and recall.
The European regulatory agency has received at least 12 reports of inflammation of the brain, which include three fatalities, possibly linked to the drug. These are in addition to Zinbryta patients reporting severe immune reactions and damage to several organs. According to its website, the FDA is aware of these reports of suspected encephalitis and meningoencephalitis cases and is conducting a review of similar events.
The drug was developed to treat relapsing forms of multiple sclerosis by inhibiting the inflammation response of T cells and increasing immune cells. When released, the FDA added a warning on the label due to risks of liver damage. In November, the EMA began restricting its use due to serious liver damage. Three months later the EMA issued an urgent review of the drug as cases of inflammation of the brain began to be reported from Germany and Spain.
Multiple sclerosis is a disease of the central nervous system where the immune system attacks the myelin sheath of the nerves. When the myelin and the nerves are damaged, nerves are unable to function correctly which may lead to blurred vision, balance and coordination issues, tremors, slurred speech, memory issues, paralysis and more. It is estimated more than 2.3-million people worldwide have MS.
More than 8,000 MS patients have taken the self-administered drug.
If you or a family member have been injured by Zinbryta contact our office to explore your legal recourse options. We can be reached on online, by phone at 877-221-2511 or request a free case evaluation online.